Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
Globe Newswire•26/10/2026•17:05 ET
0
Key Highlights
- ➤Nyxoah (NYXH) will release third-quarter 2026 financial results November 5, 2026
- ➤Management will host the Q3 2026 earnings call at 4:30 pm ET
- ➤Nyxoah received FDA approval for Genio in August 2025
- ➤Genio received CE Mark approval for expanded indications including CCC patients
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the third quarter of 2026 on Thursday, November 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET.
Get started
Create a free account to read the full story.